Animal Models of Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 186

human pro alpha 1(I) collagen gene into Mov-13 cells. J Virol
1987;61(8):2549-54.
[21] Jaenisch R, Harbers K, Schnieke A, et al. Germline integration
of moloney murine leukemia virus at the Mov13 locus leads to
recessive lethal mutation and early embryonic death. Cell 1983;
32(1):209-16.
[22] Bonadio J, Jepsen KJ, Mansoura MK, Jaenisch R, Kuhn JL,
Goldstein SA. A murine skeletal adaptation that signiicantly
increases cortical bone mechanical properties. Implications for
human skeletal fragility. J Clin Invest 1993;92(4):1697-705.
[23] Kratochwil K, von der Mark K, Kollar EJ, et al. Retrovirus-
induced insertional mutation in Mov13 mice affects collagen I
expression in a tissue-speciic manner. Cell 1989;57(5):807-16.
[24] Schnieke A, Harbers K, Jaenisch R. Embryonic lethal mutation
in mice induced by retrovirus insertion into the alpha 1(I) col-
lagen gene. Nature 1983;304(5924):315-20.
[25] Sokolov BP, Mays PK, Khillan JS, Prockop DJ. Tissue- and devel-
opment-speciic expression in transgenic mice of a type I procol-
lagen (COL1A1) minigene construct with 2.3 kb of the promoter
region and 2 kb of the 3′-lanking region. Speciicity is indepen-
dent of the putative regulatory sequences in the irst intron.
Biochemistry 1993;32(35):9242-9.
[26] Khillan JS, Li SW, Prockop DJ. Partial rescue of a lethal pheno-
type of fragile bones in transgenic mice with a chimeric anti-
sense gene directed against a mutated collagen gene. Proc Natl
Acad Sci USA 1994;91(14):6298-302.
[27] Stacey A, Bateman J, Choi T, Mascara T, Cole W, Jaenisch R.
Perinatal lethal osteogenesis imperfecta in transgenic mice
bearing an engineered mutant pro-[alpha]1(I) collagen gene.
Nature 1988;332(6160):131-6.
[28] Bateman JF, Mascara T, Cole WG, Stacey A, Jaenisch R. The
study of collagen structure and function by site-directed muta-
genesis of collagen genes. Ann N Y Acad Sci 1990;580:324-9.
[29] Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC. Use of the
Cre/lox recombination system to develop a non-lethal knock-
in murine model for osteogenesis imperfecta with an alpha1(I)
G349C substitution. Variability in phenotype in BrtlIV mice.
J Biol Chem 1999;274(53):37923-31.
[30] Sarafova AP, Choi H, Forlino A, et al. Three novel type I colla-
gen mutations in osteogenesis imperfecta type IV probands are
associated with discrepancies between electrophoretic migra-
tion of osteoblast and ibroblast collagen. Hum Mutat 1998;11(5):
395-403.
[31] Genovese C, Brufsky A, Shapiro J, Rowe D. Detection of muta-
tions in human type I collagen mRNA in osteogenesis imper-
fecta by indirect RNase protection. J Biol Chem 1989;264(16):
9632-7.
[32] Uveges TE, Collin-Osdoby P, Cabral WA, et al. Cellular mecha-
nism of decreased bone in Brtl mouse model of OI: imbalance
of decreased osteoblast function and increased osteoclasts and
their precursors. J Bone Miner Res 2008;23(12):1983-94.
[33] Kozloff KM, Carden A, Bergwitz C, et al. Brittle IV mouse
model for osteogenesis imperfecta IV demonstrates postpuber-
tal adaptations to improve whole bone strength. J Bone Miner
Res 2004;19(4):614-22.
[34] Davis MS, Kovacic BL, Marini JC, Shih AJ, Kozloff KM.
Increased susceptibility to microdamage in Brtl/+ mouse
model for osteogenesis imperfecta. Bone 2012;50(3):784-91.
[35] Blair-Levy JM, Watts CE, Fiorentino NM, Dimitriadis EK,
Marini JC, Lipsky PE. A type I collagen defect leads to rapidly
progressive osteoarthritis in a mouse model. Arthritis Rheum
2008;58(4):1096-106.
[36] Forlino A, Kuznetsova NV, Marini JC, Leikin S. Selective
retention and degradation of molecules with a single mutant
alpha1(I) chain in the Brtl IV mouse model of OI. Matrix Biol
2007;26(8):604-14.

[37] Forlino A, Tani C, Rossi A, et al. Differential expression of both
extracellular and intracellular proteins is involved in the lethal
or nonlethal phenotypic variation of BrtlIV, a murine model for
osteogenesis imperfecta. Proteomics 2007;7(11):1877-91.
[38] Panaroni C, Gioia R, Lupi A, et al. In utero transplantation of
adult bone marrow decreases perinatal lethality and rescues
the bone phenotype in the knockin murine model for classical,
dominant osteogenesis imperfecta. Blood 2009;114(2):459-68.
[39] Gioia R, Panaroni C, Besio R, et al. Impaired osteoblastogen-
esis in a murine model of dominant osteogenesis imperfecta
(OI), a new target for OI pharmacological therapy. Stem Cells
2012;30(7):1465-76.
[40] Kuznetsova NV, Forlino A, Cabral WA, Marini JC, Leikin S.
Structure, stability and interactions of type I collagen with
GLY349-CYS substitution in alpha 1(I) chain in a murine
Osteogenesis Imperfecta model. Matrix Biol 2004;23(2):101-12.
[41] Wallace JM, Orr BG, Marini JC, Holl MM. Nanoscale morphol-
ogy of Type I collagen is altered in the Brtl mouse model of
osteogenesis imperfecta. J Struct Biol 2011;173(1):146-52.
[42] Roschger P, Fratzl-Zelman N, Misof BM, Glorieux FH,
Klaushofer K, Rauch F. Evidence that abnormal high bone min-
eralization in growing children with osteogenesis imperfecta is
not associated with speciic collagen mutations. Calcif Tissue
Int 2008;82(4):263-70.
[43] Uveges TE, Kozloff KM, Ty JM, et al. Alendronate treatment
of the brtl osteogenesis imperfecta mouse improves femoral
geometry and load response before fracture but decreases pre-
dicted material properties and has detrimental effects on osteo-
blasts and bone formation. J Bone Miner Res 2009;24(5):849-59.
[44] Franklin SS. Cardiovascular risks related to increased diastolic,
systolic and pulse pressure. An epidemiologist's point of view.
Pathol Biol (Paris) 1999;47(6):594-603.
[45] Chipman SD, Sweet HO, McBride Jr DJ, et al. Defective pro
alpha 2(I) collagen synthesis in a recessive mutation in mice: a
model of human osteogenesis imperfecta. Proc Natl Acad Sci
USA 1993;90(5):1701-5.
[46] McBride Jr DJ, Shapiro JR. Conirmation of a G nucleotide dele-
tion in the Cola-2 gene of mice with the osteogenesis imper-
fecta mutation. Genomics 1994;20(1):135-7.
[47] Phillips CL, Bradley DA, Schlotzhauer CL, et al. Oim mice
exhibit altered femur and incisor mineral composition and
decreased bone mineral density. Bone 2000;27(2):219-26.
[48] McBride Jr DJ, Shapiro JR, Dunn MG. Bone geometry and
strength measurements in aging mice with the oim mutation.
Calcif Tissue Int 1998;62(2):172-6.
[49] Camacho NP, Hou L, Toledano TR, et al. The material basis
for reduced mechanical properties in oim mice bones. J Bone
Miner Res 1999;14(2):264-72.
[50] Saban J, Zussman MA, Havey R, Patwardhan AG, Schneider
GB, King D. Heterozygous oim mice exhibit a mild form of
osteogenesis imperfecta. Bone 1996;19(6):575-9.
[51] Carleton SM, McBride DJ, Carson WL, et al. Role of genetic
background in determining phenotypic severity throughout
postnatal development and at peak bone mass in Col1a2 dei-
cient mice (oim). Bone 2008;42(4):681-94.
[52] Miller E, Delos D, Baldini T, Wright TM, Pleshko Camacho N.
Abnormal mineral-matrix interactions are a signiicant con-
tributor to fragility in oim/oim bone. Calcif Tissue Int 2007;
81(3):206-14.
[53] Kuznetsova NV, McBride DJ, Leikin S. Changes in thermal
stability and microunfolding pattern of collagen helix result-
ing from the loss of alpha2(I) chain in osteogenesis imperfecta
murine. J Mol Biol 2003;331(1):191-200.
[54] Misof K, Landis WJ, Klaushofer K, Fratzl P. Collagen from the
osteogenesis imperfecta mouse model (oim) shows reduced
resistance against tensile stress. J Clin Invest 1997;100(1):40-5.